Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details)

v3.25.2
Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
May 30, 2025
Mar. 09, 2025
Jul. 31, 2025
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2025
Jun. 30, 2024
Proceeds from sale of subsidiary interests           $ 6,086 $ 0
Other liabilities           464 (94)
Noncontrolling Interest, Decrease from Deconsolidation         $ 9,931 9,931  
Gain from deconsolidation of subsidiary         $ 27,127 $ 27,127 $ 0
Checkpoint Merger              
Proceeds from sale of subsidiary interests       $ 25,100      
Other liabilities $ 10,800            
Noncontrolling Interest, Decrease from Deconsolidation $ 9,900            
Subsequent events | Checkpoint Merger              
Proceeds from sale of subsidiary interests     $ 2,900        
Checkpoint Merger              
Excess over per share exercise price for warrants   $ 4.1          
Cash payment per share   $ 3.62          
Warrants issued   5,853,659          
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc.              
Stock purchase, price per share   $ 4.1          
Maximum contingent consideration per each outstanding share   $ 0.7          
Milestone deadline date determination term   36 months          
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc. | If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of once every three weeks              
Contingent cash consideration upon achievement of milestone   $ 700          
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc. | If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of more frequent than once every three weeks              
Contingent cash consideration upon achievement of milestone   450          
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc. | If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule once every three weeks              
Contingent cash consideration upon achievement of milestone   450          
Checkpoint Merger | Checkpoint Merger | Sun Pharmaceutical Industries, Inc. | If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule more frequent than once every three weeks              
Contingent cash consideration upon achievement of milestone   $ 200          
Checkpoint Merger | Subsequent events              
Proceeds from sale of subsidiary interests     $ 2,900